Get the Stockscreener App
26.19
7.03%
-1.98
After Hours:
26.18
-0.01
-0.04%
Oruka Therapeutics Inc stock is traded at $26.19, with a volume of 412.20K.
It is down -7.03% in the last 24 hours and up +32.34% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$28.17
Open:
$28.17
24h Volume:
412.20K
Relative Volume:
1.20
Market Cap:
$980.84M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.45%
1M Performance:
+32.34%
6M Performance:
+144.54%
1Y Performance:
-3.68%
1-Day Range:
$25.84
$28.17
1-Week Range:
$25.84
$29.46
52-Week Range:
$5.485
$29.46
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
26.19 | 1.36B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-27-25 | Initiated | Guggenheim | Buy |
| Oct-13-25 | Initiated | Barclays | Overweight |
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderWeekly Stock Report & Fast Moving Trade Plans - newser.com
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - newser.com
Can Oruka Therapeutics Inc. stock sustain market leadershipWeekly Stock Report & Smart Swing Trading Techniques - newser.com
Tools to monitor Oruka Therapeutics Inc. recovery probabilitySwing Trade & Expert Curated Trade Setups - newser.com
What technical charts say about Oruka Therapeutics Inc. stockTrade Volume Report & Weekly Market Pulse Updates - newser.com
How Oruka Therapeutics Inc. (HQ1) stock behaves in tightening cycles2025 Price Targets & Long-Term Investment Growth Plans - newser.com
Why retail investors favor Oruka Therapeutics Inc. stockForecast Cut & Capital Efficient Trade Techniques - newser.com
Can Oruka Therapeutics Inc. (HQ1) stock hold up in economic slowdown2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
What valuation ratios show for Oruka Therapeutics Inc. (HQ1) stockJuly 2025 Momentum & Reliable Intraday Trade Plans - newser.com
Why Oruka Therapeutics Inc. stock attracts global investorsDollar Strength & Free High Accuracy Swing Entry Alerts - newser.com
Will Oruka Therapeutics Inc. stock recover faster than market2025 Institutional Moves & Weekly Watchlist for Hot Stocks - newser.com
Is Oruka Therapeutics Inc. stock supported by strong cash flowsMarket Sentiment Report & Weekly Sector Rotation Insights - newser.com
Is Oruka Therapeutics Inc. stock a bargain at current levelsIPO Watch & Weekly Chart Analysis and Trade Guides - newser.com
Key metrics from Oruka Therapeutics Inc.’s quarterly data2025 Top Gainers & Fast Entry Momentum Alerts - newser.com
Volume spikes in Oruka Therapeutics Inc. stock – what they meanFed Meeting & Safe Capital Allocation Plans - newser.com
Will Oruka Therapeutics Inc. (HQ1) stock return to pre crash levels2025 Support & Resistance & Safe Entry Zone Tips - newser.com
What technical patterns form on Oruka Therapeutics Inc. (HQ1) stock chartsPortfolio Risk Summary & AI Powered Market Trend Analysis - newser.com
Will Oruka Therapeutics Inc. stock outperform growth indexes2025 Sector Review & AI Based Buy/Sell Signal Reports - newser.com
What analysts say about Oruka Therapeutics Inc stockCovered Call Writing & Control Your Emotions With Discipline Tools - earlytimes.in
Published on: 2025-10-31 04:52:14 - newser.com
Price action breakdown for Oruka Therapeutics Inc.Insider Buying & Verified Entry Point Detection - newser.com
Pattern recognition hints at Oruka Therapeutics Inc. upside2025 Historical Comparison & Reliable Volume Spike Alerts - newser.com
Will Oruka Therapeutics Inc. stock go up soonGap Down & Entry and Exit Point Strategies - newser.com
HC Wainwright Brokers Raise Earnings Estimates for ORKA - MarketBeat
Q3 EPS Forecast for Oruka Therapeutics Boosted by Analyst - Defense World
Published on: 2025-10-29 21:32:46 - newser.com
Wall Street Analysts Predict a 63.59% Upside in Oruka Therapeutics, Inc. (ORKA): Here's What You Should Know - sharewise.com
Oruka Therapeutics to Present at Multiple November Investor Conferences - The Manila Times
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):